Friday, July 10, 2026
🇺🇸 FDA

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS

Telethon Foundation clinical programs — 162 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Telethon Foundation projects

162 ClinicalTrials.gov programs sponsored by Telethon Foundation.

Telethon Foundation has 162 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

162 programs

Clinical programs

Page 2 of 4

  1. CA209-6E8, CNN-BC

    Fondazione Telethon ETS

    Patients with non-metastatic muscle invasive bladder cancer

    phase 2 small molecule active

    1 trial

  2. CABOMETYX for bladder carcinoma of urothelial…

    Fondazione Telethon ETS

    bladder carcinoma of urothelial and non-urothelial histology

    phase 2 small molecule active

    1 trial

  3. CABOZANTINIB

    Fondazione Telethon ETS

    Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.

    phase 2 small molecule active

    1 trial

  4. CABinMET

    Fondazione Telethon ETS

    Non small-cell lung cancer

    phase 2 small molecule active

    1 trial

  5. CADILLACC TRIAL

    Fondazione Telethon ETS

    locally advanced cervical carcinoma

    phase 2 small molecule active

    1 trial

  6. CAPECITABINE , VALPROIC ACID

    Fondazione Telethon ETS

    low- risk rectal cancel

    phase 2 small molecule active

    1 trial

  7. CAPECITABINE for Colon cancer

    Fondazione Telethon ETS

    Colon cancer

    phase 2 small molecule active

    1 trial

  8. CAPLAND

    Fondazione Telethon ETS

    Advanced or metastatic untreated EGFR mutation positive NSCLC

    phase 2 small molecule active

    1 trial

  9. CAPTURE

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  10. CAT-PSY

    Fondazione Telethon ETS

    Substance-Induced Psychosis

    phase 2 small molecule active

    1 trial

  11. CEMIPLIMAB

    Fondazione Telethon ETS

    surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous Cell Carcinoma, Cutaneaous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. CETUXIMAB for ADCC, Colorectal Cancer

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  13. CHALLENGE

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. CML1624

    Fondazione Telethon ETS

    BCR-ABL1+ Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. CNAO 44 2021C

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  16. COOPERATION 2.0

    Fondazione Telethon ETS

    Patients with connective tissue diseases at high risk of interstial lung disease

    phase 2 other active

    1 trial

  17. CPT002/2018/PO001

    Fondazione Telethon ETS

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  18. Calcio levofolinato Teva Generics polvere per...

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  19. DARATUMUMAB for Relapsed or Refractory Plasmablastic lymphoma

    Fondazione Telethon ETS

    Relapsed or Refractory Plasmablastic lymphoma

    phase 2 small molecule active

    1 trial

  20. DEDALO

    Fondazione Telethon ETS

    Multiple Myeloma relapsed and/or refractory

    phase 2 small molecule active

    1 trial

  21. DIPG

    Fondazione Telethon ETS

    Diffuse intrinsic pontine glioma

    phase 2 small molecule active

    1 trial

  22. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. ECLYPse

    Fondazione Telethon ETS

    Patients affected by mCRC harbouring BRAF V600E

    phase 2 small molecule active

    1 trial

  24. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  25. FIL_COLUMN

    Fondazione Telethon ETS

    Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  26. FIL_MOZART

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 2 small molecule active

    1 trial

  27. FIL_RI-CHOP

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  28. FIL_V-RBAC

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  29. Fluorouracile AHCL /ml for colorectal cancer

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  30. Forxiga 10 mg film-coated tablets

    Fondazione Telethon ETS

    Chemotherapy-induced cardiotoxicity in breast cancer

    phase 2 small molecule active

    1 trial

  31. GIM35-RIBOSIL

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  32. GIMEMA ALL2922

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  33. IBRUTINIB

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis

    phase 2 small molecule active

    1 trial

  34. IFOM-CPT008/2022/PO0

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  35. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  36. INAVOLISIB

    Fondazione Telethon ETS

    endometrial cancer

    phase 2 small molecule active

    1 trial

  37. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  38. INES

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  39. IPSTYL for advanced progressive gastro-int…

    Fondazione Telethon ETS

    advanced progressive gastro-intestinal or lung carcinoids

    phase 2 small molecule active

    1 trial

  40. JEMPERLI for HPV-negative Head and Neck Squa…

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  41. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions

    phase 2 small molecule active

    1 trial

  42. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  43. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  44. LIMBAL STEM CELLS, AUTOLOGOUS

    Fondazione Telethon ETS

    low back pain

    phase 2 small molecule active

    1 trial

  45. LOLA trial

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

  46. Lynparza film-coated tablets for recurrent ovarian cancer wild t…

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  47. MATRIx

    Fondazione Telethon ETS

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  48. MELISSA

    Fondazione Telethon ETS

    Relapsed Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Telethon Foundation have?

162 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.